Keros Therapeutics (NASDAQ:KROS) Announces Quarterly Earnings Results, Misses Estimates By $0.13 EPS

Keros Therapeutics (NASDAQ:KROS) released its quarterly earnings results on Wednesday. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13), Briefing.com reports. Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. The company had revenue of $0.39 million during the quarter. During the same period in the previous year, the company posted ($1.33) earnings per share. Keros Therapeutics’s quarterly revenue was up 4750.0% on a year-over-year basis.

Keros Therapeutics Stock Up 1.1 %

Shares of Keros Therapeutics stock traded up $0.70 on Thursday, hitting $67.15. 267,653 shares of the company were exchanged, compared to its average volume of 368,905. Keros Therapeutics has a 1-year low of $27.31 and a 1-year high of $73.00. The stock has a market capitalization of $2.52 billion, a price-to-earnings ratio of -13.09 and a beta of 1.23. The company has a 50-day moving average price of $57.30 and a 200 day moving average price of $51.99.

Analysts Set New Price Targets

A number of equities research analysts recently commented on KROS shares. Wedbush reiterated an “outperform” rating and set a $84.00 price target on shares of Keros Therapeutics in a report on Thursday. Bank of America cut their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research report on Thursday, September 12th. Jefferies Financial Group started coverage on shares of Keros Therapeutics in a report on Tuesday. They set a “buy” rating on the stock. Guggenheim assumed coverage on shares of Keros Therapeutics in a research note on Monday, September 23rd. They issued a “buy” rating and a $96.00 price objective on the stock. Finally, Cantor Fitzgerald started coverage on shares of Keros Therapeutics in a research note on Thursday, October 24th. They set an “overweight” rating on the stock. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $88.89.

Insiders Place Their Bets

In related news, Director Carl L. Gordon sold 250,000 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total value of $11,002,500.00. Following the completion of the sale, the director now owns 119,522 shares of the company’s stock, valued at approximately $5,260,163.22. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 22.90% of the stock is currently owned by corporate insiders.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.